Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double- blind, parallel-group, placebo-controlled trial Dr Andrew R Goudie, MD, Prof Brian J Lipworth, MD, Pippa J Hopkinson, Li Wei, PhD, Prof Allan D Struthers, MD The Lancet Respiratory Medicine Volume 2, Issue 4, Pages 293-300 (April 2014) DOI: 10.1016/S2213-2600(14)70013-X Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile *Ruptured abdominal aortic aneurysm; ventilator-associated pneumonia after exacerbation of chronic obstructive pulmonary disease. †Admitted to hospital. The Lancet Respiratory Medicine 2014 2, 293-300DOI: (10.1016/S2213-2600(14)70013-X) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 2 Mean change in 6MWD between groups over time Error bars 95% CIs. 6MWD=6 min walking distance. The Lancet Respiratory Medicine 2014 2, 293-300DOI: (10.1016/S2213-2600(14)70013-X) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 3 Effects of one 50 mg dose of sildenafil on SpO2 over time n=120. SpO2=peripheral oxygen saturations. The Lancet Respiratory Medicine 2014 2, 293-300DOI: (10.1016/S2213-2600(14)70013-X) Copyright © 2014 Elsevier Ltd Terms and Conditions